These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 16359437)

  • 1. New strategies for the medical treatment of prostate cancer.
    Isaacs JT
    BJU Int; 2005 Dec; 96 Suppl 2():35-40. PubMed ID: 16359437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted therapeutic approaches for hormone-refractory prostate cancer.
    Stavridi F; Karapanagiotou EM; Syrigos KN
    Cancer Treat Rev; 2010 Apr; 36(2):122-30. PubMed ID: 20106600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted, gene-directed enzyme prodrug therapies to tackle diversity and aggression of late stage prostate cancer.
    Khatri A; Russell PJ
    Discov Med; 2007 Feb; 7(37):39-45. PubMed ID: 17343804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Targeted therapies for hormone-refractory prostate cancer].
    Song HZ; Chen LB
    Zhonghua Nan Ke Xue; 2010 Dec; 16(12):1108-12. PubMed ID: 21348204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer.
    Denmeade SR; Jakobsen CM; Janssen S; Khan SR; Garrett ES; Lilja H; Christensen SB; Isaacs JT
    J Natl Cancer Inst; 2003 Jul; 95(13):990-1000. PubMed ID: 12837835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted prodrug approaches for hormone refractory prostate cancer.
    Aloysius H; Hu L
    Med Res Rev; 2015 May; 35(3):554-85. PubMed ID: 25529338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antisense oligodeoxynucleotide therapy targeting clusterin gene for prostate cancer: Vancouver experience from discovery to clinic.
    Miyake H; Hara I; Gleave ME
    Int J Urol; 2005 Sep; 12(9):785-94. PubMed ID: 16201973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles.
    Tamura K; Furihata M; Tsunoda T; Ashida S; Takata R; Obara W; Yoshioka H; Daigo Y; Nasu Y; Kumon H; Konaka H; Namiki M; Tozawa K; Kohri K; Tanji N; Yokoyama M; Shimazui T; Akaza H; Mizutani Y; Miki T; Fujioka T; Shuin T; Nakamura Y; Nakagawa H
    Cancer Res; 2007 Jun; 67(11):5117-25. PubMed ID: 17545589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tranilast inhibits hormone refractory prostate cancer cell proliferation and suppresses transforming growth factor beta1-associated osteoblastic changes.
    Izumi K; Mizokami A; Li YQ; Narimoto K; Sugimoto K; Kadono Y; Kitagawa Y; Konaka H; Koh E; Keller ET; Namiki M
    Prostate; 2009 Aug; 69(11):1222-34. PubMed ID: 19434660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The mitogen-activated protein kinase phosphatase vaccinia H1-related protein inhibits apoptosis in prostate cancer cells and is overexpressed in prostate cancer.
    Arnoldussen YJ; Lorenzo PI; Pretorius ME; Waehre H; Risberg B; Maelandsmo GM; Danielsen HE; Saatcioglu F
    Cancer Res; 2008 Nov; 68(22):9255-64. PubMed ID: 19010898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Achieving treatment goals for hormone-refractory prostate cancer with chemotherapy.
    Berry W; Eisenberger M
    Oncologist; 2005; 10 Suppl 3():30-9. PubMed ID: 16368869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel targets and approaches in advanced prostate cancer.
    Hadaschik BA; Sowery RD; Gleave ME
    Curr Opin Urol; 2007 May; 17(3):182-7. PubMed ID: 17414516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic approach to hormone-refractory prostate cancer.
    Saad F; Al Dejmah A; Perrotte P; McCormack M; Bénard F; Valiquette L; Karakiewicz PI
    Can J Urol; 2006 Apr; 13 Suppl 2():52-6. PubMed ID: 16672130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo knockdown of the androgen receptor results in growth inhibition and regression of well-established, castration-resistant prostate tumors.
    Snoek R; Cheng H; Margiotti K; Wafa LA; Wong CA; Wong EC; Fazli L; Nelson CC; Gleave ME; Rennie PS
    Clin Cancer Res; 2009 Jan; 15(1):39-47. PubMed ID: 19118031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hormone refractory prostate cancer (HRPC): present and future approaches of therapy.
    Di Lorenzo G; De Placido S
    Int J Immunopathol Pharmacol; 2006; 19(1):11-34. PubMed ID: 16569343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Par-4-dependent apoptosis by the dietary compound withaferin A in prostate cancer cells.
    Srinivasan S; Ranga RS; Burikhanov R; Han SS; Chendil D
    Cancer Res; 2007 Jan; 67(1):246-53. PubMed ID: 17185378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II trial of dexamethasone, vitamin D, and carboplatin in patients with hormone-refractory prostate cancer.
    Flaig TW; Barqawi A; Miller G; Kane M; Zeng C; Crawford ED; Glodé LM
    Cancer; 2006 Jul; 107(2):266-74. PubMed ID: 16779800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prednisone monotherapy in asymptomatic hormone refractory prostate cancer.
    Heng DY; Chi KN
    Can J Urol; 2006 Dec; 13(6):3335-9. PubMed ID: 17187697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 5alpha-androstane-3alpha,17beta-diol supports human prostate cancer cell survival and proliferation through androgen receptor-independent signaling pathways: implication of androgen-independent prostate cancer progression.
    Yang Q; Titus MA; Fung KM; Lin HK
    J Cell Biochem; 2008 Aug; 104(5):1612-24. PubMed ID: 18320593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Actual chemotherapeutical possibilities in hormone-refractory prostate cancer (HRPC) patients.
    Prezioso D; Galasso R; Di Martino M; Iapicca G; Annunziata E; Iacono F
    Anticancer Res; 2007; 27(2):1095-104. PubMed ID: 17465249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.